Article Text

Download PDFPDF
Complex association of lipoprotein(a) with aortic stenosis
  1. Maximillian A Rogers1,
  2. Elena Aikawa1,2,3
  1. 1Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
  2. 2Center for Excellence in Vascular Biology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
  3. 3Department of Human Pathology, Sechenov First Moscow State Medical University, Moscow, Russia
  1. Correspondence to Dr Maximillian A Rogers, Medicine, Harvard Medical School, Boston, MA 02115, United States; MROGERS{at}; Dr Elena Aikawa, Medicine, Harvard Medical School, Boston, MA 02115, United States; eaikawa{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Aortic stenosis is a growing worldwide health burden with no approved therapies beyond surgical or transcatheter valve replacement procedures. Calcification of aortic valve leaflets is a major contributor to aortic stenosis, subsequent heart failure and ultimately death. A small number of genetic contributors to valvular calcification have been identified, with elevated lipoprotein(a) (Lp(a)) being one of the strongest risk factors for calcific aortic valve disease (CAVD).1 Despite >1 billion people globally having elevated Lp(a) (>30 to 50 mg/dL or >75 to 125 nmol/L),2 the normal physiological function of Lp(a) and how Lp(a) mechanistically promotes CAVD progression have not been established. As such, identifying the roles that Lp(a) plays in human disease is a major unmet medical need with far-reaching therapeutic potential. In their Heart paper, Capoulade et al3 assessed Lp(a) complexes with apolipoproteins and oxidised phospholipids (OxPLs) in patients from the Aortic Stenosis Progression Observation: Measuring Effects of Rousvastatin trial. This new clinical report demonstrates the novel finding that complexes of Lp(a) with apolipoprotein CIII (apoCIII) are associated with accelerated CAVD progression, in addition to validating4 the association of apolipoprotein(a) (apo(a))-OxPL complexes with accelerated CAVD progression.

Lp(a) is a low-density lipoprotein-like particle with apo(a) …

View Full Text


  • MAR and EA are joint senior authors.

  • Contributors MAR wrote the manuscript and EA edited and critically revised the manuscript.

  • Funding This work is supported by National Institutes of Health grants R01HL136431, R01HL14917 and R01HL147095.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Aortic and vascular disease
    Romain Capoulade Michael Torzewski Manuel Mayr Kwan-Leung Chan Patrick Mathieu Yohan Bossé Jean G Dumesnil James Tam Koon K Teo Sean A. Burnap Jens Schmid Nora Gobel Ulrich F W Franke Amber Sanchez Joseph L Witztum Xiaohong Yang Calvin Yeang Benoit Arsenault Jean-Pierre Després Philippe Pibarot Sotirios Tsimikas